With advancements in the treatment of various cancer types, there is a growing interest in comprehending the overall repercussions of a cancer diagnosis over the remaining lifespan. Apart from the traditional survival probabilities, calculating life expectancy post-cancer diagnosis and the subsequent loss in life expectancy for cancer patients relative to those without cancer offers valuable insights into the societal impact of cancer.
This exploration also sheds light on the advancements in cancer control initiatives and the disparities in cancer survival rates among diverse demographic groups.
In a study from Karolinska Institutet, Ph.D. student Yuliya Leontyeva from the Department of Medical Epidemiology and Biostatistics tackled methodological hurdles in determining the years remaining after a cancer diagnosis (LEC) and the associated loss in life years due to cancer (LLE) within the Relative Survival framework. The objective of the research was to enhance the applicability and accessibility of these estimations in both epidemiological and cancer survival contexts.
The research project utilized statistical techniques for population-based cancer survival analyses. Flexible Parametric Relative Survival models were employed to calculate LEC and LLE. While validating the existing approach for estimating LEC and LLE, the study introduced innovative methodologies to overcome limitations in specific scenarios.
Moreover, LEC and LLE were estimated for individuals with Myeloproliferative neoplasms, an area previously unexplored due to its complexity. The findings indicated that individuals with MPN exhibit reduced LEC and LLE compared to the general population across all MPN subtypes and age groups at diagnosis. Furthermore, the estimation of LEC and LLE was extended to small geographical regions, accompanied by the publication of accessible code to promote broader utilization.
When asked about the motivation behind this topic, Yuliya Leontyeva shared, “Initially, I was intrigued by the methodological intricacies involved in estimating LEC and LLE. However, as I delved deeper into the research project and gained more insights into cancer survival, I recognized the significance of LEC and LLE as complementary metrics to survival probabilities. By addressing methodological challenges and broadening the application of LEC and LLE, this thesis contributes to a more holistic comprehension of cancer survival.”
Regarding future research directions, Yuliya Leontyeva emphasized the necessity for further studies to address persisting challenges and advance our comprehension of cancer survival. Areas such as extrapolation for estimating LEC and LLE in individuals diagnosed with cancer before the age of 50 warrant more in-depth exploration. Additionally, investigating the estimation of LEC and LLE for diseases with indolent courses or conditions beyond cancer presents an intriguing avenue for future research, offering ample opportunities for those interested in statistical analysis.
More information:
Exploring statistical models for predicting remaining life years and loss in life expectancy for cancer patients.
Citation:
Key insights from statistical modeling of cancer patient life expectancy (2024, April 3) retrieved 3 April 2024 from https://medicalxpress.com/news/2024-04-key-insights-statistical-cancer-patient.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.